CBT 3112

Drug Profile

CBT 3112

Alternative Names: CBT-3112

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator COARE Biotechnology
  • Class Antibodies; Antineoplastics; Drug conjugates
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer; Pancreatic cancer

Highest Development Phases

  • Preclinical Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 04 Aug 2016 CBT 3112 is available for licensing as of 04 Aug 2016. http://coarebiotechnology.com/
  • 04 Aug 2016 Preclinical trials in Colorectal cancer in USA (unspecified route)
  • 04 Aug 2016 Preclinical trials in Pancreatic cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top